ArticleNature communications2024

Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043.

Yousef Zakharia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.